![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00809835 |
We are testing to see if Galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to CBT using an innovative CBT computer program.
Condition | Intervention | Phase |
---|---|---|
Cocaine Dependence |
Drug: Galantamine Drug: placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Efficacy Study |
Official Title: | Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals |
Estimated Enrollment: | 30 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Active Galantamine and CBT in addition to methadone
|
Drug: Galantamine
Daily 8 mg galantamine capsule in addition to methadone initially (first week) and 16 mg galantamine capsule as maintenance dose for remaining 7 weeks.
|
2: Placebo Comparator
Placebo dose of galantamine in addition to CBT and methadone
|
Drug: placebo
Placebo dose of "galantamine"
|
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Galina Portnoy, BA | 203-386-8802 ext 114 | gportnoy@abhct.com |
United States, Connecticut | |
Reginal Network of Programs | Recruiting |
Stratford, Connecticut, United States, 06614 |
Principal Investigator: | Kathleen M Carroll, Ph.D. | Yale University |
Responsible Party: | Yale University ( Kathleen Carroll, PhD ) |
Study ID Numbers: | 0708002943, R37 DA 15969 |
Study First Received: | December 16, 2008 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00809835 |
Health Authority: | United States: Federal Government |
Cocaine Methadone CBT |
Cocaine-Related Disorders Galantamine Disorders of Environmental Origin Naphazoline Methadone Oxymetazoline Dopamine |
Mental Disorders Phenylephrine Guaifenesin Substance-Related Disorders Phenylpropanolamine Cocaine |
Dopamine Uptake Inhibitors Parasympathomimetics Respiratory System Agents Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anesthetics Cholinergic Agents Sensory System Agents Therapeutic Uses Vasoconstrictor Agents Analgesics Analgesics, Opioid |
Nootropic Agents Central Nervous System Depressants Enzyme Inhibitors Narcotics Cardiovascular Agents Anesthetics, Local Pharmacologic Actions Cholinesterase Inhibitors Autonomic Agents Dopamine Agents Peripheral Nervous System Agents Antitussive Agents Central Nervous System Agents |